Dupixent has been approved for CSU in Japan and the United Arab Emirates (UAE) and is also under regulatory review in the European Union based on earlier trial readouts. Outside of Japan and the UAE, ...

Eupraxia Pharma reports positive data from RESOLVE phase 1b/2a trial of EP-104GI for treatment of eosinophilic esophagitis: Victoria, British Columbia Thursday, November 14, 2024, ...

Eupraxia Pharmaceuticals (TSE:EPRX) has released an update. Eupraxia Pharmaceuticals is hosting a webinar on November 15, 2024, focusing on Eosinophilic Esophagitis, a rapidly growing digestive ...

Within two days of the election, Newsom positioned himself at the forefront of the opposition, calling for state lawmakers to convene an emergency special session "to safeguard California values" in ...

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology ...

Eupraxia Pharmaceuticals (EPRX)announced additional positive clinical data from its RESOLVE Phase 1b/2a trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

Researchers used pharmacovigilance data to examine the onset of gastrointestinal adverse events associated with the use of biologic therapies for psoriasis.

17,18 TSLP is released in response to multiple triggers (including allergens, viruses and other airborne particles) ...

A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its ...